Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma

Table 2 Statistical analysis of Dot blot data showing sensitivity or specificity for autoantibody levels for ANXA1

Group comparison	p value	Summary	AUC	Sensitivity (%)	Specificity (%)
GBC stage I and II vs Healthy	0.0177	*	0.6545	25	92.68
GBC stage IIIA vs Healthy	0.0155	*	0.7395	18.18	82.93
GBC stage IIIB vs Healthy	0.0789	ns	0.7561	33.33	87.8
GBC stage IVB vs Healthy	0.2635	ns	0.5483	17.39	92.68
GBC stage I and II vs GSD	0.0007	***	0.724	41.67	95.83
GBC stage IIIA vs GSD	0.0009	***	0.8011	45.45	91.67
GBC stage IIIB vs GSD	0.1043	ns	0.7153	33.33	91.67
GBC stage IVB vs GSD	0.0419	*	0.5951	17.39	91.67
GBC Early stage vs All controls	0.0005	***	0.6919	41.67	89.89
GBC Advance stage vs All controls	0.0206	*	0.5822	15.00	89.89
LN negative vs All controls	< 0.0001	***	0.7306	30.43	89.89
LN positive vs All controls	0.2102	ns	0.5099	13.79	89.89
All cases vs All controls	0.0037	**	0.6075	15.38	95.51

GBC Gallbladder carcinomas, GSD Gallstone disease, AUC area under curve, CI confidence interval, ns not significant

ISSN: 1471-2407